Osmotica pharmaceuticals plc (OSMT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17
Revenues

48,649

59,911

65,461

57,532

57,126

65,696

66,344

71,858

59,800

53,741

Cost of goods sold (inclusive of amortization of intangibles)

20,590

22,470

27,312

32,643

29,203

39,487

33,356

33,676

33,561

21,464

Gross profit

28,059

37,440

38,148

24,888

27,923

26,208

32,988

38,182

26,239

32,276

Selling, general and administrative expenses

21,176

21,110

24,751

25,512

21,656

22,953

17,451

16,675

17,161

13,258

Research and development expenses

5,688

8,909

8,285

5,360

9,764

12,686

11,964

8,866

10,174

6,492

Impairment of intangibles

-

-

128,113

125,765

-

-

6,173

-

-

30,747

Impairment of goodwill

-

-

0

-

-

-

-

-

-

-

Total operating expenses

26,864

59,888

161,149

156,638

31,420

133,688

35,589

25,542

27,336

50,498

Operating loss

1,195

-22,447

-123,000

-131,749

-3,497

-107,479

-2,600

12,639

-1,097

-18,221

Interest expense and amortization of debt discount

4,064

4,654

4,503

4,551

4,501

5,394

5,311

5,241

4,843

7,301

Other non-operating (income) loss, net

-

-

-

-

-

-

-

-

137

1,202

Other non-operating expense

746

164

176

-14

557

4,626

434

309

-4,705

-6,098

Total other non-operating expense (gain)

-3,318

-4,489

-4,326

-4,566

-3,944

-

-4,877

-4,932

-

-

Loss before income taxes

-2,123

-26,937

-127,327

-136,316

-7,441

-113,090

-7,478

7,707

-5,802

-24,319

Income tax benefit

960

-81

-14,622

-11,662

-754

-5,735

-3,872

1,819

-1,195

-12,046

Net loss

-3,083

-26,855

-112,704

-124,653

-6,687

-107,355

-3,606

5,888

-4,607

-12,272

Other comprehensive loss, net
Change in foreign currency translation adjustments

-

-

-383

-

-

25

-148

-722

-368

292

Comprehensive loss

-

-26,855

-113,087

-124,653

-6,687

-107,329

-3,754

5,165

-4,975

-11,979

Income (loss) per share attributable to shareholders
Loss per share attributable to shareholders, basic and diluted

-0.05

-0.52

-2.15

-2.37

-0.13

-2.37

-0.08

0.14

-0.11

-

Partnership income (loss) per unit

-

-

-

-

-0.13

-

0.09

-

-

-12.27

Diluted

-

-

-

-

-

-

-

-

-

-12.27

Weighted average shares basic and diluted
Weighted average shares, basic and diluted

58,257

51,955

52,476

52,518

52,518

52,531

42,862

42,855

42,855

-

Weighted average partnership units

-

-

-

-

-

-

42,862

-

-

-

Basic and Diluted

-

-

-

-

-

-

-

-

-

1,000

Product Revenue
Revenues

47,308

58,815

64,041

56,215

56,400

65,134

65,443

71,985

58,834

-

Royalty Revenue
Revenues

869

815

1,325

779

721

303

903

-210

962

-

Licensing and Contract Revenue
Revenues

472

280

94

537

5

258

-2

83

3

-